Treatment with gefitinib after erlotinib-induced liver injury: a case report

por Nakatomi, Katsumi, Nakamura, Yoichi, Tetsuya, Iida, Kohno, Shigeru
Publicado 2011

Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction

por Shimada, Midori, Fukuda, Minoru, Fukuda, Masaaki, Kitazaki, Takeshi, Hashiguchi, Kohji, Ikeda, Takaya, Yamaguchi, Hiroyuki, Nakatomi, Katsumi, Ashizawa, Kazuto, Mukae, Hiroshi
Publicado 2017

Birth Cohort Effects on Incidence of Lung Cancers: A Population‐based Study in Nagasaki, Japan

por Soda, Hiroshi, Oka, Mikio, Soda, Midori, Nakatomi, Katsumi, Kawabata, Shigeru, Suenaga, Mitsuhiro, Kasai, Takashi, Yamada, Yasuaki, Kamihira, Shimeru, Kohno, Shigeru
Publicado 2000

Autoantibody to Heat Shock Protein Hsp40 in Sera of Lung Cancer Patients

por Oka, Mikio, Sato, Sho‐ichi, Soda, Hiroshi, Fukuda, Minoru, Kawabata, Shigeru, Nakatomi, Katsumi, Shiozawa, Ken, Nakamura, Yo‐ichi, Ohtsuka, Kenzo, Kohno, Shigeru
Publicado 2001

Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy

por Senju, Hiroaki, Kumagai, Asuka, Nakamura, Yoichi, Yamaguchi, Hiroyuki, Nakatomi, Katsumi, Fukami, Shota, Shiraishi, Kengo, Harada, Yuka, Nakamura, Mitsuhiro, Okamura, Haruki, Tanaka, Yoshimasa, Mukae, Hiroshi
Publicado 2018

Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non‐squamous non‐small cell lung cancer

por Takemoto, Shinnosuke, Nakamura, Yoichi, Fukuda, Minoru, Senju, Hiroaki, Gyotoku, Hiroshi, Taniguchi, Hirokazu, Shimada, Midori, Ikeda, Takaya, Yamaguchi, Hiroyuki, Nakatomi, Katsumi, Hayashi, Nobuyuki, Soda, Hiroshi, Mukae, Hiroshi
Publicado 2017

Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer

por Ogusu, Shinsuke, Harutani, Yuhei, Tozuka, Takehiro, Saito, Ryota, Koyama, Junji, Sakamoto, Hiroaki, Sonoda, Tomoaki, Tsuchiya-Kawano, Yuko, Oba, Tomohiro, Kudo, Keita, Gyotoku, Hiroshi, Nakatomi, Katsumi, Ariyasu, Ryo
Publicado 2023

Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan‐related toxicities in patients with lung cancer

por Fukuda, Minoru, Okumura, Manabu, Iwakiri, Tomomi, Arimori, Kazuhiko, Honda, Takuya, Kobayashi, Kazuma, Senju, Hiroaki, Takemoto, Shinnosuke, Ikeda, Takaya, Yamaguchi, Hiroyuki, Nakatomi, Katsumi, Matsuo, Nobuko, Mukae, Hiroshi, Ashizawa, Kazuto
Publicado 2017

Prediction of Anti-Cancer Drug-Induced Pneumonia in Lung Cancer Patients: Novel High-Resolution Computed Tomography Fibrosis Scoring

por Gyotoku, Hiroshi, Yamaguchi, Hiroyuki, Ishimoto, Hiroshi, Sato, Shuntaro, Taniguchi, Hirokazu, Senju, Hiroaki, Kakugawa, Tomoyuki, Nakatomi, Katsumi, Sakamoto, Noriho, Fukuda, Minoru, Obase, Yasushi, Soda, Hiroshi, Ashizawa, Kazuto, Mukae, Hiroshi
Publicado 2020

Phase II trial of a non‐platinum triplet for patients with advanced non‐small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA

por Takemoto, Shinnosuke, Nakamura, Yoichi, Gyoutoku, Hiroshi, Senju, Hiroaki, Ogawara, Daiki, Ikeda, Takaya, Yamaguchi, Hiroyuki, Kitazaki, Takeshi, Nakano, Hirofumi, Nakatomi, Katsumi, Tomari, Shinya, Sato, Shuntaro, Nagashima, Seiji, Fukuda, Minoru, Mukae, Hiroshi
Publicado 2019

Efficacy of S‐1 after pemetrexed in patients with non‐small cell lung cancer: A retrospective multi‐institutional analysis

por Takemoto, Shinnosuke, Akagi, Kazumasa, Ono, Sawana, Tomono, Hiromi, Honda, Noritaka, Suyama, Takayuki, Umeyama, Yasuhiro, Dotsu, Yosuke, Taniguchi, Hirokazu, Ogawara, Daiki, Senju, Hiroaki, Gyotoku, Hiroshi, Sugasaki, Nanae, Yamaguchi, Hiroyuki, Nakatomi, Katsumi, Fukuda, Minoru, Mukae, Hiroshi
Publicado 2021

Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study

por Takemoto, Shinnosuke, Fukuda, Minoru, Yamaguchi, Hiroyuki, Ikeda, Takaya, Akagi, Kazumasa, Tomono, Hiromi, Umeyama, Yasuhiro, Dotsu, Yosuke, Taniguchi, Hirokazu, Gyotoku, Hiroshi, Senju, Hiroaki, Kitazaki, Takeshi, Nakatomi, Katsumi, Nagashima, Seiji, Fukuda, Masaaki, Kinoshita, Akitoshi, Soda, Hiroshi, Mukae, Hiroshi
Publicado 2019

Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial

por Iwasaku, Masahiro, Uchino, Junji, Chibana, Kenji, Tanzawa, Shigeru, Yamada, Takahiro, Tobino, Kazunori, Uchida, Yasuki, Kijima, Takashi, Nakatomi, Katsumi, Izumi, Miiru, Tamiya, Nobuyo, Kimura, Hideharu, Fujita, Masaki, Honda, Ryoichi, Takumi, Chieko, Yamada, Tadaaki, Kaneko, Yoshiko, Kiyomi, Fumiaki, Takayama, Koichi
Publicado 2023

Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulati...

por Dotsu, Yosuke, Yamaguchi, Hiroyuki, Fukuda, Minoru, Suyama, Takayuki, Honda, Noritaka, Umeyama, Yasuhiro, Taniguchi, Hirokazu, Gyotoku, Hiroshi, Takemoto, Shinnosuke, Tagawa, Ryuta, Ogata, Ryosuke, Tomono, Hiromi, Shimada, Midori, Senju, Hiroaki, Nakatomi, Katsumi, Nagashima, Seiji, Soda, Hiroshi, Ikeda, Hiroaki, Ashizawa, Kazuto, Mukae, Hiroshi
Publicado 2021

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer

por Taniguchi, Hirokazu, Yamaguchi, Hiroyuki, Dotsu, Yosuke, Shimada, Midori, Gyotoku, Hiroshi, Senju, Hiroaki, Takemoto, Shinnosuke, Kitazaki, Takeshi, Fukuda, Masaaki, Ogawara, Daiki, Soda, Hiroshi, Nakatomi, Katsumi, Sugasaki, Nanae, Kinoshita, Akitoshi, Nagashima, Seiji, Ikeda, Takaya, Nakamura, Yoichi, Sakamoto, Noriho, Obase, Yasushi, Fukuda, Minoru, Mukae, Hiroshi
Publicado 2019

Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study

por Tomono, Hiromi, Taniguchi, Hirokazu, Fukuda, Minoru, Ikeda, Takaya, Nagashima, Seiji, Akagi, Kazumasa, Ono, Sawana, Umeyama, Yasuhiro, Shimada, Midori, Gyotoku, Hiroshi, Takemoto, Shinnosuke, Hisamatsu, Yasushi, Morinaga, Ryotaro, Tagawa, Ryuta, Ogata, Ryosuke, Dotsu, Yosuke, Senju, Hiroaki, Soda, Hiroshi, Nakatomi, Katsumi, Hayashi, Fumiko, Sugasaki, Nanae, Kinoshita, Akitoshi, Mukae, Hiroshi
Publicado 2023

Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited‐disease small cell lung cancer: protocol of ACIST study

por Akagi, Kazumasa, Taniguchi, Hirokazu, Fukuda, Minoru, Yamazaki, Takuya, Ono, Sawana, Tomono, Hiromi, Suyama, Takayuki, Shimada, Midori, Gyotoku, Hiroshi, Takemoto, Shinnosuke, Yamaguchi, Hiroyuki, Dotsu, Yosuke, Senju, Hiroaki, Soda, Hiroshi, Mizowaki, Takashi, Monzen, Yoshio, Ikeda, Takaya, Nagashima, Seiji, Tasaki, Yutaro, Nakamura, Daisuke, Komiya, Kazutoshi, Nakatomi, Katsumi, Sasaki, Eisuke, Hirakawa, Koichi, Mukae, Hiroshi
Publicado 2022

The role of comprehensive analysis with circulating tumor DNA in advanced non‐small cell lung cancer patients considered for osimertinib treatment

por Sueoka‐Aragane, Naoko, Nakashima, Chiho, Yoshida, Hironori, Matsumoto, Naohisa, Iwanaga, Kentaro, Ebi, Noriyuki, Nishiyama, Akihiro, Yatera, Kazuhiro, Kuyama, Shoichi, Fukuda, Minoru, Ushijima, Sunao, Umeguchi, Hitomi, Harada, Daijiro, Kashiwabara, Kosuke, Suetsugu, Takayuki, Fujimoto, Nobukazu, Tanaka, Fumihiro, Uramoto, Hidetaka, Yoshii, Chiharu, Nakatomi, Katsumi, Koh, Genju, Seki, Nobuhiko, Aoe, Keisuke, Nosaki, Kaname, Inoue, Koji, Takamori, Ayako, Kawaguchi, Atsushi
Publicado 2021